spec sheet7 rows
Alentemol is an investigational compound described as a selective dopamine autoreceptor agonist that was studied as a potential antipsychotic. It was never marketed and published pharmacology data are limited.
- Explored as a potential antipsychotic through selective dopamine autoreceptor activation
Overview
A niche dopamine-autoreceptor compound from older antipsychotic research; it never got far enough for much to be published.
Mechanism
Alentemol is described as acting selectively on autoreceptors, the presynaptic receptors that provide negative feedback on dopamine neuron firing and release. By preferentially stimulating these autoreceptors, the compound was intended to dampen excess dopaminergic activity, a rationale explored for antipsychotic effects.
receptor fingerprint
autoreceptorsAgonist
Safetyrisks and cautions, not medical advice
No detailed clinical safety or tolerability data are available in the public literature; the compound never progressed to marketed use, so its human safety profile remains unestablished.
Subjective profileweighing the evidence above
A footnote rather than a compound. Nothing was published beyond the autoreceptor rationale, no human safety data exists, and it never reached the market; there is nothing to try and nothing to base a dose on.
Resources
This entry is here for reference.
Reviews
My notesprivate to this device
FAQ
What is Alentemol used for?
Alentemol is not an approved drug. It was researched as a potential antipsychotic that acts on dopamine autoreceptors, but it was never marketed.
How does Alentemol work?
It is described as selectively stimulating dopamine autoreceptors, which provide feedback inhibition on dopamine neurons, potentially reducing excess dopaminergic activity.
Is Alentemol well-researched?
No. Publicly available information is limited to reference works and patent-era pharmaceutical literature, with no substantial published clinical trial data.
Limitations of the evidence
- Unknown; no published human safety data